Silver Creek Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Silver Creek Pharmaceuticals is a private, clinical-stage biotech developing novel biologics to rescue cells from injury. Its lead asset, scp776, is a first-in-class, targeted IGF1 fusion protein currently in a Phase II trial for acute ischemic stroke, with preclinical data suggesting potential in heart attack and kidney injury. The company leverages its proprietary 'Smart Growth Factor' platform to design therapies that aim to mitigate secondary tissue damage by inhibiting apoptosis. Leadership includes seasoned drug development executives with experience from Pfizer, Roche, and other biopharma companies.

NeurologyCardiologyNephrology

Technology Platform

Smart Growth Factor™ technology for developing targeted growth factor fusion proteins that deliver cell survival signals (e.g., IGF1) specifically to sites of tissue injury.

Opportunities

The primary opportunity is addressing the vast unmet need for neuroprotective agents in acute ischemic stroke, a multi-billion dollar market.

Preclinical data also opens significant secondary opportunities in heart attack and acute kidney injury, which are large markets with high unmet needs.

Success in one indication could validate the platform for rapid expansion into others.

Risk Factors

The company faces high clinical development risk, as its value is concentrated in a single asset (scp776) that must succeed in late-stage trials.

As a private, pre-revenue firm, it also carries significant financing risk to fund expensive Phase III studies.

There is competitive risk from other neuroprotective approaches and the challenge of demonstrating additive benefit to current standard-of-care therapies.

Competitive Landscape

In acute ischemic stroke, competition includes other neuroprotective agents in development and the expanding use of mechanical thrombectomy. The field has seen many failures, indicating high scientific and clinical hurdles. For its platform, potential competitors include other companies developing targeted biologics or apoptosis inhibitors for acute tissue injury, though Silver Creek's specific IGF1 fusion approach appears distinct.

More companies in Biologics / Biosimilars →More companies in United States →